Literature DB >> 14675090

Homocysteine levels are associated with the severity of peripheral arterial disease in Type 2 diabetic patients.

E Ciccarone1, A Di Castelnuovo, D Assanelli, S Archetti, G Ruggeri, N Salcuni, M B Donati, F Capani, L Iacoviello.   

Abstract

BACKGROUND: Homocysteine levels are positively associated with the risk of cardiovascular disease. They might be determined by both MTHFR677C-->T polymorphisms and folate or B-vitamin status.
OBJECTIVES: To investigate the possible association between plasma homocysteine levels and its genetic or environmental determinants and either the presence or the severity of peripheral arterial disease (PAD), in Type 2 diabetic patients.
METHODS: From a cohort of 944 patients with Type 2 diabetes, 135 patients with PAD were selected, and frequency-matched for age and sex with 219 Type 2 diabetic control patients without macrovascular complications. According to the increasing severity of the disease, patients were divided into PAD1 (only diffuse calcifications of the arteries without any stenosis or occlusion), PAD2 (one or two stenosis or occlusions) and PAD3 (three or more).
RESULTS: Homocysteine levels were similar in control and case patients (10.3 micromol L-1 vs. 10.7 micromol L-1, P = 0.53); however, a significant increase was found in PAD3 patients: odds ratio = 2.77 (95% confidence interval 1.14, 6.72) for patients with homocysteine levels above the median vs. those under the median in multivariate analysis. Although all significantly associated with homocysteine levels, neither MTHFR genotype nor folic acid or vitamin B12 levels were associated with severity of PAD. A significant interaction (P < 0.05) was found between folic acid and MTHFR polymorphism in determining the levels of homocysteine.
CONCLUSIONS: In Type 2 diabetes, homocysteine was associated with the angiographic severity of PAD, but neither the genotypes nor vitamin levels contributed to this association.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675090     DOI: 10.1111/j.1538-7836.2003.00500.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  7 in total

Review 1.  Biomarkers and Genetics in Peripheral Artery Disease.

Authors:  Surovi Hazarika; Brian H Annex
Journal:  Clin Chem       Date:  2016-11-21       Impact factor: 8.327

2.  Vitamin B12 level in peripheral arterial disease.

Authors:  Katalin S Zsóri; Zoltán Csiki; Éva Katona; Zsuzsnna Bereczky; Amir-Houshang Shemirani
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

Review 3.  The role of nutrition and body composition in peripheral arterial disease.

Authors:  Diana P Brostow; Alan T Hirsch; Tracie C Collins; Mindy S Kurzer
Journal:  Nat Rev Cardiol       Date:  2012-08-28       Impact factor: 32.419

4.  Comparative effect of two Mediterranean diets versus a low-fat diet on glycaemic control in individuals with type 2 diabetes.

Authors:  A Lasa; J Miranda; M Bulló; R Casas; J Salas-Salvadó; I Larretxi; R Estruch; V Ruiz-Gutiérrez; M P Portillo
Journal:  Eur J Clin Nutr       Date:  2014-02-12       Impact factor: 4.016

Review 5.  Novel markers of peripheral arterial disease.

Authors:  Farhan J Khawaja; Iftikhar J Kullo
Journal:  Vasc Med       Date:  2009-11       Impact factor: 3.239

6.  Methylenetetrahydrofolate reductase polymorphism 677C>T is associated with peripheral arterial disease in type 2 diabetes.

Authors:  Rebecca L Pollex; Mary Mamakeesick; Bernard Zinman; Stewart B Harris; Anthony J G Hanley; Robert A Hegele
Journal:  Cardiovasc Diabetol       Date:  2005-11-07       Impact factor: 9.951

7.  Association of Hyperhomocysteinemia with Increased Coronary Microcirculatory Resistance and Poor Short-Term Prognosis of Patients with Acute Myocardial Infarction after Elective Percutaneous Coronary Intervention.

Authors:  Yang-Pei Peng; Ming-Yuan Huang; Yang-Jing Xue; Jia-Lin Pan; Cong Lin
Journal:  Biomed Res Int       Date:  2020-01-02       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.